NCT01593293.
Trial name or title | A randomized, Open‐Label, Phase III Study Comparing Pemetrexed With and Without Carboplatin in Elderly Patients With Advanced Non‐Squamous Non‐Small Cell Lung Cancer |
Methods | Randomized multi‐center open‐label |
Participants | Eligibility criteria Inclusion criteria
Exclusion criteria
|
Interventions | Control arm: pemetrexed 500 mg/m2 on day 1, every 3 weeks until progression or unacceptable toxicity Experimental arm: pemetrexed 500 mg/m2 on day 1 plus carboplatin AUC5 i.v. on day 1, every 3 weeks for 4 cycles, followed by pemetrexed 500 mg/m2 on day 1, every 3 weeks for maintenance therapy |
Outcomes | Primary outcome
Secondary outcomes
|
Starting date | March 2012 |
Contact information | Sang‐We Kim, M.D.; 82‐2‐3010‐3215; email: swkim@amc.seoul.kr |
Notes |